

# Coffee and cardiac arrhythmias: Up-date review of the literature and clinical studies

Stanisław Surma<sup>1,2</sup>, Monika Romańczyk<sup>1</sup>, Krzysztof J. Filipiak<sup>3</sup>, Gregory Y.H. Lip<sup>4,5</sup>

<sup>1</sup>Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland

<sup>2</sup>Club of Young Hypertensiologists, Polish Society of Hypertension, Gdansk, Poland

<sup>3</sup>Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy in Warsaw, Poland

<sup>4</sup>Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom

<sup>5</sup>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

## Abstract

*Coffee, next to water, is the most consumed drink in the world. Coffee contains over 1000 chemical compounds, the most popular of which are caffeine, chlorogenic acid, kahweol, cafestol and trigonelline. Numerous studies have shown the beneficial effects of coffee on the cardiovascular system, nervous system, digestive system and kidneys. Due to the high incidence of cardiac arrhythmias, especially atrial fibrillation, the influence of coffee consumption on arrhythmogenesis remains a controversial and clinically important issue. Many mechanisms by which coffee can increase and decrease the risk of arrhythmias have been described. Habitual consumption of moderate amounts of coffee seems to lead to less arrhythmias, which is reflected in the results of many clinical trials and meta-analyses. This review summarizes the mechanisms of coffee action on the heart muscle and the results of the most recent important clinical trials assessing the impact of coffee consumption on the risk of various cardiac arrhythmias. (Cardiol J 2023; 30, 4: 654–667)*

**Key words:** coffee, heart arrhythmia, atrial arrhythmia, ventricular arrhythmia

## Introduction

Coffee is the most consumed drink next to water and tea. According to the National Coffee Association United States of America (USA), about 2.25 billion cups are drunk worldwide every day [1]. Data of the International Coffee Organization (ICO) indicate that inhabitants of the Netherlands consume the most coffee — on average of approximately 8.3 kg *per capita*/year (data from 2020). In 2020/2021, around 166.63 million 60-kilogram bags of coffee were consumed worldwide, a slight increase from 164 million bags in the previous year. According to data from the British Coffee Associa-

tion, 95 million cups of coffee are consumed daily in the United Kingdom (UK). In Poland, coffee consumption calculated *per capita*, is about 3.65 kg/year (on average, 1–2 cups of coffee *per capita*/day). In last 10 years of coffee consumption in Poland significantly increased by as much as over 80% [2].

The large popularity of coffee consumption in the world has led to many studies assessing its impact on human health, for example, the effects of coffee consumption on blood pressure and the risk of hypertension [3]. Another review summarizes the influence of coffee consumption on the risk of various diseases including nervous, digestive, cardiovascular and kidney disorders [4, 5].

**Address for correspondence:** Prof. Krzysztof J. Filipiak, MD, PhD, FESC, Institute of Clinical Sciences, Maria Skłodowska-Curie Medical Academy in Warsaw, Pałac Lubomirskich, ul. Plac Żelaznej Bramy 10, 00–136 Warszawa, Poland, tel: +48 22 703 43 86, e-mail: krzysztof.filipiak@uczelniamedyczna.com.pl

Received: 14.03.2022

Accepted: 11.07.2022

Early publication date: 29.07.2022

This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Regular and moderate coffee consumption seems to reduce the risk of cardiovascular- and all-cause mortality [6, 7].

The prevalence of cardiac arrhythmias, especially atrial fibrillation (AF), is high worldwide and continues to increase. In 2007, the prevalence of AF cases globally was 28,533 million, while in 2017 it was 37,574 million, and the prevalence of AF in 2050 will be over 60 million cases worldwide [8]. AF significantly increases the risk of death, cardiovascular complications, and also worsens the prognosis in patients with coronavirus disease (COVID-19) [9–11], with increasing healthcare costs [12]. Moreover, arrhythmias have been associated with psychological morbidity, including the risk of depression [13].

An important contributor to cardiac arrhythmias, including AF, is played by modifiable risk factors such as smoking, alcohol abuse, lack of physical activity and sedentary lifestyle, arterial hypertension, obesity, and inappropriate nutritional behavior [14]. Nonetheless, the influence of coffee consumption on the risk of arrhythmias remains a controversial issue. A large percentage of doctors recommend patients with heart palpitations to stop or reduce using coffee [15]. In a randomized clinical trial by Groh et al. [16], out of 957 patients with paroxysmal AF, 28% reported consumption of caffeine as a trigger for this arrhythmia.




Given the widespread consumption of coffee and the high prevalence of arrhythmias, this review summarizes the impact of consumption of this popular drink on the risk of cardiac arrhythmias.


### Coffee — A brief overview

Worldwide, from the commercial point of view, the most important types are Arabica coffee (*Coffea arabica*), robusta coffee (*Coffea canephora*) and Liberian coffee (*Coffea liberica*) (Table 1) [17–19]. The largest amounts of coffee are produced in Brazil [20]. It is estimated that there are over 1000 chemical compounds in coffee. The most common chemical compounds in coffee are phenols (chlorogenic acid, and diterpenes: kahweol, and cafestol) and alkaloids (caffeine and trigonelline). Less abundant compounds found in coffee include mannose, polysaccharide chains of galactose, melanoidins, flavonoids, catechins, anthocyanins, ferulic acid, caffeic acid, p-coumaric acid, and tocopherols [21, 22].

The composition of coffee depends on many factors, including the type of coffee (e.g., *Coffea arabica*, *Coffea canephora*, *Coffea liberica*) (Table 1), the method of production (wet, dry, semi-dry/semi-

**Table 1.** Characteristics of *Coffea arabica*, *Coffea robusta*, and *Coffea liberica* [17–19]

Type of coffee/ characteristics	Place of cultivation	Bean	Percent in the global coffee market	Aroma	Mean concentration of chemical components [g/100 g]							
					Caffeine	Water	Proteins	Sucrose + reducing sugars	Poly-saccha- rides	Lipids	Chlorogenic acid	Minerals
<i>Coffea arabica</i>	Brazil, Central America and Africa		64%	++	1.6	8.0–12.0	9.8	8.1	49.8	16.2	6.5	4.2
<i>Coffea robusta</i>	Vietnam, Brazil, Indonesia and Africa		35%	+++	2.26	8.0–12.0	9.5	4.4	54.4	10.0	10.0	4.4
<i>Coffea liberica</i>	Malaysia, some regions of the Philippines and Africa (Liberia)		1%	+	1.23	11.0	14.0	8.0	42.0	12.0	7.0	4.0




**Figure 1.** The main chemical compounds found in traditional coffee and espresso in terms of concentration and total amount in the usual serving sizes [20].

wet, and bio-processing), and the method of preparation (e.g., traditional brewed coffee, espresso) (Fig. 1) [17–19, 21–25]. Pre-harvest factors (e.g., sunlight) and post-harvest factors (e.g., method of processing coffee beans) account for approximately 40% and 60% of the organoleptic, physical, and chemical properties of coffee, respectively [17–19, 21–25]. Interestingly, the caffeine content in a cup of coffee varies by geographic region. In Northern Europe and the UK, a cup of coffee contains 140 mg of caffeine, in Southern Europe 50 mg, and in the USA 85 mg [26]. Caffeine is also found in drinks such as decaffeinated coffee, cola, green tea, black tea, and energy drinks [27].

### Effect of chemical components in coffee on cardiac electrophysiology

Since it is likely that not all of the chemical compounds present in coffee have been identified, and that the mechanisms of action of most of the identified compounds are not yet fully understood, the biological properties of coffee are currently attributed to the effects of the best described compounds, such as caffeine, chlorogenic acid, trigonelline, cafestol, and kahweol, as well as ferulic acid. Central illustration summarizes the potential biochemical mechanisms of the influence of coffee on cardiac electrophysiology.



**Central illustration.** Effect of coffee on arrhythmogenesis; A<sub>1</sub>R — adenosine A1 receptor; A<sub>2A</sub>R — adenosine A2AR receptor; AChE — acetylcholinesterase; Ach — acetylcholine; M<sub>2</sub> — muscarinic acetylcholine receptor M<sub>2</sub>; RyR — ryanodine receptors; IP<sub>3</sub>R — inositol 1,4,5-trisphosphate receptor; PDE — phosphodiesterase; NA — noradrenaline; β<sub>1</sub> — β<sub>1</sub> adrenergic receptor.

Coffee is characterized by a very complex and poorly understood effect on the electrophysiology of the heart. There are pro- and anti-arrhythmic effects of coffee. It should be emphasized, however, that the observed effect depends on whether coffee is consumed occasionally or regularly and in what amounts [28].

Caffeine interacts with different receptors in the cardiovascular system in a dose dependent manner. Occasional or very high doses of caffeine consumption may increase the risk of arrhythmias because they may lead to phosphodiesterase (PDE) inhibition [29]. Inhibition of PDE leads to an increase in the level of cyclic adenosine monophosphate (cAMP) in the cardiomyocytes, which in turn results in the phosphorylation of protein

kinase A (PKA) [30]. Another caffeine mechanism increasing PKA phosphorylation in cardiomyocytes is the increase in noradrenaline (NA) release from sympathetic nerve endings [24]. NA, through β<sub>1</sub>-adrenergic receptors, stimulating the production of cAMP [31]. PKA, by activating ryanodine receptors (RyR), stimulates the outflow of Ca<sup>2+</sup> from the sarcoplasmic reticulum (SR) into the cytoplasm [31]. Interestingly, caffeine triggers Ca<sup>2+</sup> release by reducing the threshold for luminal Ca<sup>2+</sup> activation of RyR [32]. Thus, caffeine directly and indirectly increases the release of Ca<sup>2+</sup> from SR. Increases in intracellular Ca<sup>2+</sup> are potentially pro-arrhythmic through atrial pacemaker cell automaticity and after depolarization-induced triggered activity [33]. Another mechanism by which caffeine may increase

the risk of arrhythmia is by increasing myofilament  $Ca^{2+}$  sensitivity [28, 34].

On the other hand, caffeine is an inhibitor of acetylcholinesterase (AChE), which increases the concentration of acetylcholine (ACh), which, by stimulating the  $M_2$  receptor, reduces the level of cAMP in the cell [35]. Moreover, caffeine can inhibit the activity of inositol 1,4,5-trisphosphate receptor (IP3R), which may reduce the influx of  $Ca^{2+}$  from SR into the cytoplasm [32].

Another important mechanism of caffeine's action is the non-selective antagonism of adenosine receptors ( $A_1R$  and  $A_{2A}R$ ) [27]. In the atria, adenosine exerts direct and indirect anti- $\beta$ -adrenergic effects. The activation of  $I_{K_{ado}}$ , *via*  $A_1R$  leads to shortening of action potential duration and refractoriness, thus facilitating reentry mechanisms and atrial arrhythmias. Overexpression of  $A_1R$  is associated with bradycardia, delayed conduction through the sinoatrial and atrioventricular nodes, atrial arrhythmia, and ventricular hypertrophy [36]. Adenosine, in turn, through  $A_{2A}R$  stimulates the RyR that control part of the intracellular  $Ca^{2+}$  flux from the SR storage site [36]. Taking this into account, the non-selective antagonism of  $A_1R$  and  $A_{2A}R$  by caffeine is characterized by antiarrhythmic activity, since it cannot only inhibit the onset of AF but can also impede its propagation throughout the atria *via* increased refractoriness.

Coffee is also characterized by a number of other important mechanisms of action that reduce the risk of arrhythmia, for example, antioxidant activity [37]. Indeed, coffee has a higher level of antioxidant activity (292 to 948 min) than black tea (67 to 277 min) or herbal tea (6 to 78 min), on the basis of a cup serving [38, 39]. Coffee (its chemical components) is also characterized by antihypertensive [3], anti-inflammatory [40, 41], anti-apoptotic [42], anti-fibrotic [43, 44] and anti-atherosclerotic [45–47] effects. Moreover, coffee consumption has been shown to reduce visceral adipose tissue, which is also characterized by an antiarrhythmic effect [48]. Clinical trials have shown that coffee consumption was associated with a reduced risk of heart failure (HF) [49]. It has also been suggested that the antiarrhythmic properties of coffee may result from its influence on the composition of the gut microbiota [50–52]. Chlorogenic acid may reduce the production of trimethylamine (TMA; precursor of arrhythmogenic trimethylamine N-oxide [TMAO]) [53], while coffee consumption may increase the level of *Bifidobacterium spp.* [54, 55] involved in the production of short-chain fatty

acids (SCFA), which may reduce the risk of arrhythmias [56]. It is worth mentioning that chlorogenic acid is an inhibitor of xanthine oxidase [57]. Therefore, consumption of coffee leads to a decrease in the level of uric acid, which is characterized by proarrhythmic properties [57, 58]. Coffee may also reduce the plasma concentration of lipoprotein (a) [Lp (a)], which may also contribute to reducing the risk of AF [59–61]. Coffee consumption contributes to an increase in physical activity and performance [62, 63], which also reduces the risk of arrhythmias [64].

In summary, coffee's mechanisms of action may both increase and decrease the risk of arrhythmias. It should be emphasized that regular consumption of moderate amounts of coffee leads to the development of tolerance, so that antiarrhythmic, long-term effects of coffee may become more important.

### Coffee and arrhythmias — Clinical studies

The effect of coffee consumption on the risk of arrhythmia has been assessed in numerous clinical studies. The key studies on the effect of coffee consumption on the risk of arrhythmia are summarized in Table 2 [65–104].

As previously mentioned, the risk of arrhythmia may be related to the stimulation of the sympathetic nervous system, especially with large amounts of coffee. This is confirmed by experimental and clinical studies.

In a study by Strubelt and Diederich [105], the administration of 15 mg/kg/min caffeine resulted in sympathetic over-activation, with sinus tachycardia and ventricular ectopy culminating in ventricular fibrillation in all rats, and the effects were partially reversed by administration of  $\beta$ -adrenergic receptor antagonists. This was also confirmed by Robertson et al. [106] in which healthy subjects who did not consume coffee for 3 weeks were given 250 mg of caffeine (which corresponds to 3 cups of coffee) whereby a significant increase in the concentration of norepinephrine and adrenaline by 75% and 207%, respectively, was demonstrated.

The negative effect of a high dose of coffee on the risk of arrhythmias is confirmed by de Vreede-Swagemakers et al. [95] which found that only consumption of > 10 cups of coffee/day was associated with a significant increase in the risk of sudden cardiac death. Caffeine overdose can cause life-threatening arrhythmias [107]. A significant relationship between the pattern of coffee consumption and the risk of arrhythmia was demonstrated

**Table 2.** Major studies examining the impact of coffee/caffeine on risk of arrhythmias.

Author [Ref.] (year)	Study type	N (subjects)	Findings	Conclusion
Kistler et al. [65] (2022)	Observational	502,543 subjects (34,279 with CVD)	Follow-up: > 10 years. Coffee consumption at all levels (0, < 1, 1, 2–3, 4–5, > 5 cups/day) was not associated with risk of arrhythmia including AF/atrial flutter in those with CVD. Of 24111 patients diagnosed with an arrhythmia, coffee intake was associated with mortality reduction. Lowest risk was at 1 cup/day (HR = 0.85; 95% CI: 0.78–0.94). In those with AF/atrial flutter, 1 cup/day was associated with improved survival (HR = 0.82; 95% CI: 0.73–0.93)	↔
Marcus et al. [66] (2021)	Randomized controlled	320 subjects with paroxysmal AF	Follow-up: 10 weeks. Acute exposure to alcohol increased AF risk, with no evidence that other exposures, including caffeine, more commonly triggered AF	↔
Marcus et al. [67] (2021)	Randomized controlled	100 healthy subjects	Real-time coffee consumption (> 1 cup) had no significant impact on risk PAC	↔
Krittanawong et al. [68] (2021)	<b>Meta-analysis</b>	12 studies (361,143)	Coffee consumption is not associated with the risk of new-onset AF (NS)	↔
Bazal et al. [69] (2021)	<b>Meta-analysis</b>	2 cohorts (25,462)	Consumption of caffeinated coffee (1–7 cups/week) reduced the risk of AF (HR = 0.60; 95% CI: 0.44–0.82)	↓
Kim et al. [70] (2021)	Prospective cohort with Mendelian randomization	386,258 subjects	Follow-up: 4.5 ± 3.1 years. Each additional cup of habitual coffee consumed had a positive effect on the risk of AF and/or atrial flutter (HR = 0.97; 95% CI: 0.96–0.98)	↓
Signori et al. [71] (2021)	Randomized controlled	1227 subjects with HF	Follow-up: 3 months. The effect of coffee consumption on the risk of AF was dose-related: <ul style="list-style-type: none"> <li>• 1–2 cups/day (NS)</li> <li>• ≥ 3 cups/day (HR = 0.21; 95% CI: 0.09–0.53)</li> </ul>	↔/↓
Yuan et al. [72] (2021)	Mendelian randomization	35,979 and 17,325 subjects	Coffee consumption is not associated with the risk of AF (UK Biobank and FinnGen consortium: NS)	↔
Yuan et al. [73] (2019)	Mendelian randomization	588,190 subjects	A causal relationship between habitual coffee consumption and the risk of AF has not been demonstrated (NS)	↔
Bodar et al. [74] (2019)	Prospective	18,960 males	Follow-up: 9 years. The effect of coffee consumption on the risk of AF was dose-related: <ul style="list-style-type: none"> <li>• ≤ 1 cup/week (NS)</li> <li>• 2–4 cups/week (NS)</li> <li>• 5–6 cups/week (NS)</li> <li>• 1 cup/day (HR = 0.85; 95% CI: 0.74–0.98)</li> <li>• 2–3 cups/day (HR = 0.86; 95% CI: 0.76–0.97)</li> <li>• &gt; 4 cups/day (NS)</li> </ul>	↔/↓
Xu et al. [75] (2019)	Observational	5972 subjects	Follow-up: 14 years. Nonhabitual (> 0–0.5 cups/day) consumption of coffee (HR = 1.22; 95% CI: 1.01–1.48) Habitual coffee consumption was not associated with AF risk (NS for ≥ 0.5–1.5 cups/day and NS for ≥ 1.5 cups/day)	↑/↔
Abdelfattah et al. [76] (2018)	<b>Meta-analysis</b>	8 studies (176,675)	The incidence of new-onset AF is not increased by coffee consumption (NS)	↔
Casiglia et al. [77] (2018)	Prospective cohort	1475 subjects	Follow-up: 12 years. Consumption of < 320 mg caffeine/day was not significantly associated with the risk reduction of AF, while consumption > 320 mg/day significantly reduced this risk, regardless of the CYP1A2 polymorphism (p = 0.008)	↔/↓

→

**Table 2 (cont.).** Major studies examining the impact of coffee/caffeine on risk of arrhythmias.

Author [Ref.] (year)	Study type	N (subjects)	Findings	Conclusion
Mostofsky et al. [78] (2016)	Population-based cohort	57,053 subjects	Follow-up: 13.5 years. The effect of coffee consumption on the risk of AF was dose-related: <ul style="list-style-type: none"> <li>• ≤ 1–5 cups/day (NS)</li> <li>• 6–7 cups/day (HR = 0.79; 95% CI: 0.64–0.98)</li> <li>• &gt; 7 cups/day (NS)</li> </ul>	↔/↓
Dixit et al. [79] (2016)	Observational	1388 subjects	No correlation between atrial ectopics/h and intake of coffee (p = 0.28)	↔
Larsson et al. [80] (2015)	<b>Meta-analysis</b>	6 studies (248,910)	Highest vs. lowest category of coffee consumption (NS). Increment of coffee consumption per 2 cups/day (NS)	↔
Larsson et al. [80] (2015)	Population-based cohort	76,475 subjects	Follow-up: 12 years. Coffee consumption has not been shown to influence the risk of AF. <ul style="list-style-type: none"> <li>• &lt; 2–≥ 5 cups/day: HR = NS</li> </ul>	↔
Cheng et al. [81] (2014)	<b>Meta-analysis</b>	6 studies (228,465)	After smoking adjusting beneficial effect of coffee on the risk of AF: low dose of coffee (RR = 0.89; 95% CI: 0.80–0.99) and high dose of coffee (RR = 0.84; 95% CI: 0.75–0.94)	↓
Caldeira et al. [82] (2013)	<b>Meta-analysis</b>	7 studies (115,993)	Consumption of < 350 mg caffeine/day was associated with a 15% reduction in the risk of AF (OR = 0.85; 95% CI: 0.78–0.92)	↓
Klatsky et al. [83] (2011)	Retrospective population cohort	130,054 subjects	Follow-up: 17.6 years. In most cases, coffee consumption did not affect the risk of hospitalization for AF and atrial flutter: <ul style="list-style-type: none"> <li>• &lt; 1 cup/day (NS)</li> <li>• 1–3 cups/day (NS)</li> <li>• ≥ 4 cups/day (AF risk: HR = 0.81; 95% CI: 0.69–0.96; atrial flutter: NS)</li> <li>• Per cup per day (NS)</li> </ul>	↔/↓
Mattioli et al. [84] (2011)	Observational	247 hypertensive subjects	Consumption of 1– > 3 cups of coffee/day was not significantly associated with the risk of spontaneous conversion of AF	↔
Shen et al. [85] (2011)	Prospective cohort	4526 subjects	Consumption of caffeine was not significantly associated with AF risk. Q1, Q2, Q3 and Q4: NS	↔
Conen et al. [86] (2010)	Randomized controlled	33,638 women	Follow-up: 14.4 years. The effect of coffee consumption on the risk of AF was dose-related: <ul style="list-style-type: none"> <li>• 0 to &lt; 1 cup/day (NS)</li> <li>• 1 cup/day (NS)</li> <li>• 2–3 cups/day (RR = 1.36; 95% CI: 1.12–1.65)</li> <li>• ≥ 4 cups/day (NS)</li> </ul>	↑/↔
Mukamal et al. [87] (2009)	Prospective cohort	33,538 subjects with MI	Follow-up: 6.6–9.9 years. Coffee consumption ≥ 1 cup/day was not associated with adjusted HR for AF (HR = NS)	↔
Mattioli et al. [88] (2008)	Comparative	400 subjects	The effect of coffee consumption on the risk of AF was dose-related: <ul style="list-style-type: none"> <li>• 1–3 cups/day (OR = 0.02; 95% CI: 0.013–0.086)</li> <li>• &gt; 3 cups/day (OR = 3.14; 95% CI: 1.864–3.35)</li> </ul> Consumption of > 3 cups of coffee/day was not significantly associated with the persistent AF	↑/↔/↓
Frost et al. [89] (2005)	Prospective cohort	47,949 subjects	Follow-up: 5.7 years. When the lowest quintile of caffeine consumption was used as a reference, the adjusted HR in quintiles 2, 3, 4, and 5 were insignificant	↔
Mattioli et al. [90] (2005)	Case control	116 subjects	High coffee intake, > 3 cups/day, was associated with a lower rate of spontaneous cardioversion from AF (OR = 0.3; 95% CI: 0.11–0.49)	↔



**Table 2 (cont.).** Major studies examining the impact of coffee/caffeine on risk of arrhythmias.

Author [Ref.] (year)	Study type	N (subjects)	Findings	Conclusion
Wilhelmsen et al. [91] (2001)	Population-based cohort	7495 subjects	Follow-up: 25.2 years. Consumption of $\geq 5$ cups/day was not significantly associated with a higher risk of incident AF, although moderate consumption reached borderline significance (OR = 1.24; 95% CI: 1.00–1.54)	$\leftrightarrow$
<b>Ventricular arrhythmia (VA)</b>				
Marcus et al. [67] (2021)	Randomized controlled	100 healthy subjects	Real-time coffee consumption ( $> 1$ cup) had no impact on risk of VT episodes. Consuming $> 1$ cup of coffee significantly increased the risk of PVC (consumption $\leq 1$ cup did not increase this risk significantly). Moreover, faster caffeine metabolizers experienced a heightened risk of PVC	$\leftrightarrow$
Zuchinali et al. [92] (2016)	<b>Meta-analysis</b>	7 studies (290 subjects)	Coffee consumption did not affect the rate of ventricular premature beats (high dose: NS; low dose: NS)	$\leftrightarrow$
Zuchinali et al. [93] (2016)	Randomized controlled	51 subjects with HF	Acute caffeine ingestion (500 mg over 5 h) vs. placebo did not increase VPBs (185 vs. 239, respectively; $p = 0.47$ ) or nonsustained VT in patients with moderate to severe LV dysfunction	$\leftrightarrow$
Bertoia et al. [94] (2013)	Randomized controlled	93,676 post-menopausal women	Follow-up: 11 years. No association between coffee consumption ( $p = 0.84$ ) and risk of sudden cardiac death	$\leftrightarrow$
Klatsky et al. [83] (2011)	Retrospective population cohort	4526 subjects	Follow-up: 17.6 years. In most cases, coffee consumption did not affect the risk of hospitalization for ventricular fibrillation/flutter/cardiac arrest: <ul style="list-style-type: none"> <li><math>&lt; 1</math> cup/day (NS)</li> <li>1–3 cups/day (NS)</li> <li><math>\geq 4</math> cups/day (HR = 0.47; 95% CI: 0.23–0.96)</li> <li>Per cup per day (NS)</li> </ul>	$\leftrightarrow/\downarrow$
de Vreede-Swagemakers et al. [95] (1999)	Case control	117 subjects with CAD	Only very heavy coffee consumption ( $> 10$ cups/day) was associated with a higher risk of sudden cardiac arrest (OR = 55.7; 95% CI: 6.4–483). Consumption 1–9 cups of coffee/day was not a significant risk factor	$\uparrow/\leftrightarrow$
Newby et al. [96] (1996)	Randomized controlled	13 subjects with idiopathic VPB	Follow-up: 6 weeks. No significant changes in palpitation scores or VPB frequencies during the intervention weeks and no significant correlations were found between these variables and serum caffeine concentrations	$\leftrightarrow$
Myers et al. [97] (1990)	Randomized controlled	35 subjects with MI	Moderately high doses of caffeine (450 mg/day) do not appear to increase ventricular arrhythmias	$\leftrightarrow$
Graboyes et al. [98] (1989)	Crossover	50 subjects with malignant VA	In subjects with structural heart disease, hourly VPBs burden and nonsustained VT did not differ between the caffeine and placebo	$\leftrightarrow$
Myers et al. [99] (1987)	Randomized controlled	70 subjects	In 7-day post-MI patients, continuous Holter monitoring did not show a difference in percentage of patients who had VPBs, nor VPB burden after 300 mg of caffeine vs. placebo	$\leftrightarrow$
Prineas et al. [100] (1980)	Cross-sectional	7311 subjects	Compared with consumption of $\leq 2$ cups of coffee/day ( $t = 2.90$ ; $p < 0.005$ ) was positively associated with the presence of VPBs, with $> 9$ cups of coffee associated with twice the risk of VPBs in healthy subjects	$\uparrow$

→



**Table 2 (cont.).** Major studies examining the impact of coffee/caffeine on risk of arrhythmias.

Author [Ref.] (year)	Study type	N (subjects)	Findings	Conclusion
<b>Tachyarrhythmias</b>				
Kim et al. [70] (2021)	Prospective cohort with Mendelian randomization	386,258 subjects	Follow-up: 4.5 ± 3.1 years. Each additional cup of habitual coffee consumed was inversely associated with the risk of SVT (HR = 0.96; 95% CI: 0.94–0.99)	↓
Marcus et al. [67] (2021)	Randomized controlled	100 healthy subjects	Real-time coffee consumption (> 1 cup) had no impact on risk of SVT episodes	↔
de Oliveira et al. [101] (2017)	Cross-sectional	15,105 subjects	Follow-up: 12 months. The association between coffee consumption and HRV reduction disappears for HRV indexes after adjusting for potential confounding factors	↔
Dixit et al. [79] (2016)	Observational	1388 subjects	No correlation between supraventricular tachycardia runs and intake of coffee (p = 0.22)	↔
Lemery et al. [102] (2015)	Prospective randomized controlled	80 subjects with symptomatic SVT	Caffeine 5 mg/kg bw (moderate intake) or placebo. Electrocardiography examination after 57 ± 13 min after caffeine consumption. <ul style="list-style-type: none"> <li>• Heart rate (NS difference)</li> <li>• Effective refractory period of atrium or ventricle (NS difference)</li> <li>• Atrioventricular node conduction (NS difference)</li> <li>• SVT (NS difference)</li> </ul>	↔
Notarius et al. [103] (2012)	Randomized controlled	21 subjects	Caffeine enhances cardiac parasympathetic activity and reduces sympathetic outflow to the skeletal muscle in middle-aged healthy subjects, but has no effects on HRV or MSNA in CHF subjects	↔/↓
Klatsky et al. [83] (2011)	Retrospective population cohort	4526 subjects	Follow-up: 17.6 years. In most cases, coffee consumption did not affect the risk of hospitalization for PST and PVT: <ul style="list-style-type: none"> <li>• &lt; 1 cup/day (NS)</li> <li>• 1–3 cups/day (NS)</li> <li>• ≥ 4 cups/day (PVT risk: HR = 0.63; 95% CI: 0.41–0.98; PST: NS)</li> <li>• Per cup per day (NS)</li> </ul>	↔/↓
Richardson et al. [104] (2009)	Randomized controlled	103 subjects with STEMI	Follow-up: 5 days. There was no detrimental effect of regular coffee consumption on cardiac rhythm post-STEMI	↔

AF — atrial fibrillation; CAD — coronary artery disease; CHF — congestive heart failure; CI — confidence interval; CVD — cardiovascular disease; HF — heart failure; HR — hazard ratio; HRV — heart rate variability; LV — left ventricle; MI — myocardial infarction; MSNA — muscle sympathetic nerve activity; NS — not significant; OR — odds ratio; PAC — premature atrial contractions; PST — paroxysmal supraventricular tachycardia; PVC — premature ventricular contractions; PVT — paroxysmal ventricular tachycardia; Q — quartile; RR — relative risk; STEMI — ST-segment elevation myocardial infarction; SVT — supraventricular tachycardia; VPB — ventricular premature beats; VT — ventricular tachycardia

by Xu et al. [75] whereby subjects who consumed coffee in a non-habitual manner had a 22% higher risk of AF than those who did not consume coffee. Such a relationship has not been demonstrated in subjects habitually consuming coffee [75].

In a prospective Mendelian randomized controlled trial by Kim et al. [70] the influence of coffee consumption on the incident tachyarrhythmias was assessed. The study covered 386,258 subjects, who were followed on average for 4.5 years. Habitual coffee consumption was found to be associated

with a significant, but small, reduction in the risk of incident arrhythmia (hazard ratio [HR] = 0.97; 95% confidence interval [CI]: 0.96–0.98, p < 0.001). The analysis by type of arrhythmia also showed a similar effect of habitual coffee consumption on the risk of AF and/or atrial flutter (HR = 0.97; 95% CI: 0.96–0.98, p < 0.001) and supraventricular tachycardia (HR = 0.96; 95% CI: 0.94–0.99, p = 0.002) [70].

The influence of habitual coffee consumption on the risk of ventricular tachycardia, premature

atrial complex and premature ventricular complex has not been demonstrated. Importantly, Mendelian randomization failed to provide evidence that caffeine consumption was associated with arrhythmias [70]. In a randomized clinical trial, involving 320 patients with paroxysmal AF followed-up for 10 weeks, acute exposure to alcohol increased AF risk, but no such effect of caffeine consumption was shown [66]. Another randomized study, Coffee And Real-time Atrial And Ventricular Ectopy (CRAVE) involving 100 healthy subjects followed for 13.3 days, assessed the effect of coffee consumption on the risk of real-time arrhythmias [67]. Consumption of > 1 cup of coffee/day had no effect on the risk of premature atrial contractions (relative risk [RR] = 0.81; 95% CI: 0.51–1.29), supraventricular tachycardia (RR = 0.83; 95% CI: 0.63–1.10) and ventricular tachycardia. However, consumption of > 1 cup of coffee/day increased the risk of premature ventricular contractions (RR = 2.20; 95% CI: 1.24–3.92), especially in intermediate and fast caffeine metabolizers. Of note, they studied acute effects, and included healthy volunteers (not arrhythmia patients), participants were not blinded to the intervention, did not have continuous electrocardiography rhythms and that genetic variants or other behaviors may modify the observed effects [67].

In a randomized study by Zuchinali et al. [93] including 51 patients with HF, acute caffeine ingestion (500 mg over 5 h) vs. placebo did not increase ventricular premature beats. Interestingly, a randomized study involving 1227 patients with HF who were followed for 3 months, found that coffee consumption ( $\geq 3$  cups/day) may reduce the risk of AF [71]. Similar results were obtained by Bodar et al. [74], who studied 18,960 males followed for 9 years, whereby consumption of 2–3 cups of coffee/day reduced the risk of AF occurrence. On the other hand, Mendelian randomized studies [72, 73] showed no association between coffee consumption and the risk of AF. In a prospective study involving 1475 participants followed for 12 years, caffeine consumption > 320 mg/day significantly reduced the risk of AF, regardless of the *CYP1A2* polymorphism ( $p = 0.008$ ) [77].

The relationship between coffee consumption and the risk of arrhythmias has been summarized in several meta-analyses. In a meta-analysis of 12 clinical trials, no effect of coffee consumption on the risk of new-onset AF was found [68]. The same results were obtained in another meta-analysis of 8 studies by Abdelfattah et al. [76]. Moreover, a meta-analysis of 2 studies by Bazal et al. [69] found that coffee consumption (1–7 cups/week

may reduce the risk of AF. The beneficial effect of coffee consumption were also found in previous meta-analyses by Cheng et al. [81], and Caldeira et al. [82]. With regard to ventricular arrhythmias, a meta-analysis of 7 studies by Zuchinali et al. [92] did not show that coffee consumption influenced of rate of ventricular premature beats.

The study by Kistler et al. [65], which included 502,543 subjects from UK Biobank, showed that regular coffee intake is shown to be safe in prevalent cardiovascular disease with no increase in risk of arrhythmia. Survival benefit with coffee intake was observed in those with prevalent arrhythmia. Thus, coffee should not be discouraged in patients with prevalent cardiovascular disease and arrhythmia.

Aside from arrhythmias, the Coronary Artery Risk Development in Young Adults (CARDIA) clinical study showed that low-to-moderate daily coffee consumption from early adulthood to middle age was associated with better left ventricular systolic and diastolic function in midlife [108]. High daily coffee consumption (> 4 cups/day) was associated with worse left ventricular function, while there was no association between pure caffeine or tea intake and cardiac function [108].

In conclusion, the results of numerous clinical trials (randomized, prospective, randomized Mendelian, etc.) and meta-analyses indicate that habitual consumption of coffee in moderate amounts (2–3 cups of coffee/day) does not increase the risk of arrhythmia, and might even reduce it slightly. While coffee consumption may increase the risk of premature ventricular contractions, these results are inconsistent and require further study.

### Limitations of research on the effect of coffee on arrhythmias

The most important limitation of studies thus far is that it is not known exactly which coffee was consumed by the participants (type, blend, country of origin, type of grain treatment, preparation method, additives — milk and/or sugar, and the different definitions of a cup of coffee). As discussed, many factors influence the biological properties of coffee. Another limitation is the influence of the diet of the respondents, as well as polymorphisms of numerous genes of enzymes involved in the metabolism of coffee chemical components (these polymorphisms may differ between the participants of the cited studies), which may cause different sensitivity of the respondents to coffee and thus the occurrence of various biological effects after its consumption.

Another limitation is that some studies have used caffeine instead of coffee, which only allows indirect conclusions about how coffee works. The reason is the presence of many other chemical compounds in coffee, which are also biologically active. Recently, an important role of epigenetics has been pointed out, which would explain the different effects of coffee observed in various studies (coffee consumption is associated with different levels of DNA methylation in many CpG sites) [109].

Also, most meta-analyses are based on the results of observational studies, which makes it impossible to assess the cause-and-effect relationship. All this means that the possibility of interpreting and comparing the results is limited. Of note, people tend to naturally regulate their coffee consumption based on blood pressure levels and heart rate, hence observational studies of habitual coffee intakes are prone to influences by reverse causation, and caution is required when inferred health benefits result from comparisons with coffee abstainers or decaffeinated coffee drinkers [110].

### Conclusions and clinical perspectives

Based on the present literature review, consuming 2–3 cups of black coffee (without milk and sugar) daily should not increase arrhythmias in the general population. Separate studies, however, are awaited in some populations, such as those with paroxysmal AF, HF with reduced ejection fraction, those after different arrhythmia ablation procedures, etc. Moreover, there are a lack of data on the safety of coffee consumption by patients after AF ablation. In some subpopulations, such as pregnant women, coffee consumption remains controversial and should be closely monitored [111]. As so many beneficial effects of coffee drinking have been researched on, the cardiovascular perspective on coffee has improved over the years, and we are perhaps looking at coffee more as a friend than foe.

**Conflict of interest:** None declared

### References

1. <https://www.ncausa.org/> (access: 25th, Jan, 2022).
2. <https://anamsuperlink.blogspot.com/2017/09/secret-billions-of-people-drink-coffee.html> (access: 25th, Jan, 2022).
3. Surma S, Oparil S. Coffee and arterial hypertension. *Curr Hypertens Rep.* 2021; 23(7): 38, doi: [10.1007/s11906-021-01156-3](https://doi.org/10.1007/s11906-021-01156-3), indexed in Pubmed: 34370111.
4. Surma S, Kokot F. Influence of chronic coffee consumption on the risk of kidney and other organ diseases. *Renal Disease Transplantation Forum.* 2022; 15(1): 1–18, doi: [10.5603/RDTE2021.0015](https://doi.org/10.5603/RDTE2021.0015).
5. Mazidi M, Mikhailidis DP, Dehghan A, et al. The association between coffee and caffeine consumption and renal function:

insight from individual-level data, Mendelian randomization, and meta-analysis. *Arch Med Sci.* 2022; 18(4): 900–911, doi: [10.5114/aoms/144905](https://doi.org/10.5114/aoms/144905), indexed in Pubmed: 35832703.

6. Grosso G, Micek A, Godos J, et al. Coffee consumption and risk of all-cause, cardiovascular, and cancer mortality in smokers and non-smokers: a dose-response meta-analysis. *Eur J Epidemiol.* 2016; 31(12): 1191–1205, doi: [10.1007/s10654-016-0202-2](https://doi.org/10.1007/s10654-016-0202-2), indexed in Pubmed: 27699514.
7. Surma S, Banach M. Coffee and caffeine consumption and overall mortality. *Pleasure with restrictions - where do we really stand in 2022?* *Nutrition.* 2022 [Epub ahead of print]: 111747, doi: [10.1016/j.nut.2022.111747](https://doi.org/10.1016/j.nut.2022.111747), indexed in Pubmed: 35843767.
8. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. *Int J Stroke.* 2021; 16(2): 217–221, doi: [10.1177/1747493019897870](https://doi.org/10.1177/1747493019897870), indexed in Pubmed: 31955707.
9. Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ.* 2016; 354: i4482, doi: [10.1136/bmj.i4482](https://doi.org/10.1136/bmj.i4482), indexed in Pubmed: 27599725.
10. Harrison SL, Fazio-Eynullayeva E, Lane DA, et al. Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19. *J Arrhythm.* 2021; 37(1): 231–237, doi: [10.1002/joa3.12458](https://doi.org/10.1002/joa3.12458), indexed in Pubmed: 33664908.
11. Romiti GF, Corica B, Lip GYH, et al. Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19: a systematic review and meta-analysis. *J Clin Med.* 2021; 10(11): 2490, doi: [10.3390/jcm10112490](https://doi.org/10.3390/jcm10112490), indexed in Pubmed: 34199857.
12. Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. *Eur Heart J Qual Care Clin Outcomes.* 2022; 8(2): 187–194, doi: [10.1093/ehjqcco/qcaa093](https://doi.org/10.1093/ehjqcco/qcaa093), indexed in Pubmed: 33346822.
13. Mikhaylov AY, Yumashev AV, Kolpak E. Quality of life, anxiety and depressive disorders in patients with extrasystolic arrhythmia. *Arch Med Sci.* 2022; 18(2): 328–335, doi: [10.5114/aoms.2020.101359](https://doi.org/10.5114/aoms.2020.101359), indexed in Pubmed: 35316917.
14. Gorenek B, Pelliccia A, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). *Europace.* 2017; 19(2): 190–225, doi: [10.1093/europace/euw242](https://doi.org/10.1093/europace/euw242), indexed in Pubmed: 28175283.
15. Hughes J, Amori G, Hatsukami D. A survey of physician advice about caffeine. *J Substance Abuse.* 1988; 1(1): 67–70, doi: [10.1016/s0899-3289\(88\)80009-9](https://doi.org/10.1016/s0899-3289(88)80009-9).
16. Groh CA, Faulkner M, Getabecha S, et al. Patient-reported triggers of paroxysmal atrial fibrillation. *Heart Rhythm.* 2019; 16(7): 996–1002, doi: [10.1016/j.hrthm.2019.01.027](https://doi.org/10.1016/j.hrthm.2019.01.027), indexed in Pubmed: 30772533.
17. Rao NZ, Fuller M, Grim MD. Physiochemical characteristics of hot and cold brew coffee chemistry: the effects of roast level and brewing temperature on compound extraction. *Foods.* 2020; 9(7), doi: [10.3390/foods9070902](https://doi.org/10.3390/foods9070902), indexed in Pubmed: 32659894.
18. Keng-Chee SA, Wan-Sinn Y, Keng-Chong W, et al. Comparative study of the volatile constituents of southeast asian Coffea arabica, Coffea liberica and Coffea robusta green beans and their antioxidant activities. *Journal of Essential Oil Bearing Plants.* 2015; 18(1): 64–73, doi: [10.1080/0972060x.2014.977580](https://doi.org/10.1080/0972060x.2014.977580).
19. Rubayiza AB, Meurens M. Chemical discrimination of arabica and robusta coffees by Fourier transform Raman spectroscopy. *J Agric Food Chem.* 2005; 53(12): 4654–4659, doi: [10.1021/jf0478657](https://doi.org/10.1021/jf0478657), indexed in Pubmed: 15941296.
20. Romualdo GR, Rocha AB, Vinken M, et al. Drinking for protection? Epidemiological and experimental evidence on the beneficial

- effects of coffee or major coffee compounds against gastrointestinal and liver carcinogenesis. *Food Res Int.* 2019; 123: 567–589, doi: [10.1016/j.foodres.2019.05.029](https://doi.org/10.1016/j.foodres.2019.05.029), indexed in Pubmed: 31285007.
21. Gonzalez de Mejia E, Ramirez-Mares MV. Impact of caffeine and coffee on our health. *Trends Endocrinol Metab.* 2014; 25(10): 489–492, doi: [10.1016/j.tem.2014.07.003](https://doi.org/10.1016/j.tem.2014.07.003), indexed in Pubmed: 25124982.
  22. de Melo Pereira GV, de Carvalho Neto DP, Magalhães Júnior AI, et al. Chemical composition and health properties of coffee and coffee by-products. *Adv Food Nutr Res.* 2020; 91: 65–96, doi: [10.1016/bs.afnr.2019.10.002](https://doi.org/10.1016/bs.afnr.2019.10.002), indexed in Pubmed: 32035601.
  23. Wintgens J. Coffee: Growing, Processing, Sustainable Production. A Guidebook for Growers, Processors, Traders and Researchers. Weinheim, Germany: Wiley-VCH; Factors influencing the quality of green coffee; 2009; pp. 797–817.
  24. Nieber K. The impact of coffee on health. *Planta Med.* 2017; 83(16): 1256–1263, doi: [10.1055/s-0043-115007](https://doi.org/10.1055/s-0043-115007), indexed in Pubmed: 28675917.
  25. Eun JB, Jo MY, Im JS. Physicochemical characteristics of coffee extracts using different extraction methods. *Korean J Food Sci Technol.* 2014; 46(6): 723–728, doi: [10.9721/kjfst.2014.46.6.723](https://doi.org/10.9721/kjfst.2014.46.6.723).
  26. McCusker RR, Goldberger BA, Cone EJ. Caffeine content of specialty coffees. *J Anal Toxicol.* 2003; 27(7): 520–522, doi: [10.1093/jat/27.7.520](https://doi.org/10.1093/jat/27.7.520), indexed in Pubmed: 14607010.
  27. Voskoboinik A, Kalman JM, Kistler PM. Caffeine and arrhythmias: time to grind the data. *JACC Clin Electrophysiol.* 2018; 4(4): 425–432, doi: [10.1016/j.jacep.2018.01.012](https://doi.org/10.1016/j.jacep.2018.01.012), indexed in Pubmed: 30067480.
  28. Voskoboinik A, Koh Y, Kistler PM. Cardiovascular effects of caffeinated beverages. *Trends Cardiovasc Med.* 2019; 29(6): 345–350, doi: [10.1016/j.tcm.2018.09.019](https://doi.org/10.1016/j.tcm.2018.09.019), indexed in Pubmed: 30301595.
  29. Voskoboinik A, Prabhu S, Sugumar H, et al. Effect of dietary factors on cardiac rhythm. *Am J Cardiol.* 2018; 122(7): 1265–1271, doi: [10.1016/j.amjcard.2018.06.019](https://doi.org/10.1016/j.amjcard.2018.06.019), indexed in Pubmed: 30075892.
  30. Tulsian NK, Krishnamurthy S, Anand GS. Channeling of cAMP in PDE-PKA Complexes Promotes Signal Adaptation. *Biophys J.* 2017; 112(12): 2552–2566, doi: [10.1016/j.bpj.2017.04.045](https://doi.org/10.1016/j.bpj.2017.04.045), indexed in Pubmed: 28636912.
  31. Spadari RC, Cavadas C, de Carvalho AE, et al. Role of beta-adrenergic receptors and sirtuin signaling in the heart during aging, heart failure, and adaptation to stress. *Cell Mol Neurobiol.* 2018; 38(1): 109–120, doi: [10.1007/s10571-017-0557-2](https://doi.org/10.1007/s10571-017-0557-2), indexed in Pubmed: 29063982.
  32. Woll KA, Van Petegem F. Calcium-release channels: structure and function of IP receptors and ryanodine receptors. *Physiol Rev.* 2022; 102(1): 209–268, doi: [10.1152/physrev.00033.2020](https://doi.org/10.1152/physrev.00033.2020), indexed in Pubmed: 34280054.
  33. Artin B, Singh M, Richeh C, et al. Caffeine-related atrial fibrillation. *Am J Ther.* 2010; 17(5): e169–e171, doi: [10.1097/MJT.0b013e3181df8cf8](https://doi.org/10.1097/MJT.0b013e3181df8cf8), indexed in Pubmed: 20634688.
  34. Huke S, Knollmann BC. Increased myofilament Ca<sup>2+</sup>-sensitivity and arrhythmia susceptibility. *J Mol Cell Cardiol.* 2010; 48(5): 824–833, doi: [10.1016/j.yjmcc.2010.01.011](https://doi.org/10.1016/j.yjmcc.2010.01.011), indexed in Pubmed: 20097204.
  35. Pohanka M, Dobes P. Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase. *Int J Mol Sci.* 2013; 14(5): 9873–9882, doi: [10.3390/ijms14059873](https://doi.org/10.3390/ijms14059873), indexed in Pubmed: 23698772.
  36. Guieu R, Deharo JC, Maille B, et al. Adenosine and the cardiovascular system: the good and the bad. *J Clin Med.* 2020; 9(5), doi: [10.3390/jcm9051366](https://doi.org/10.3390/jcm9051366), indexed in Pubmed: 32384746.
  37. Metro D, Cernaro V, Santoro D, et al. Beneficial effects of oral pure caffeine on oxidative stress. *J Clin Transl Endocrinol.* 2017; 10: 22–27, doi: [10.1016/j.jcte.2017.10.001](https://doi.org/10.1016/j.jcte.2017.10.001), indexed in Pubmed: 29204368.
  38. Richelle M, Tavazzi I, Offord E. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. *J Agric Food Chem.* 2001; 49(7): 3438–3442, doi: [10.1021/jf0101410](https://doi.org/10.1021/jf0101410), indexed in Pubmed: 11453788.
  39. Olechno E, Puścion-Jakubik A, Socha K, et al. Coffee infusions: can they be a source of microelements with antioxidant properties? *Antioxidants (Basel).* 2021; 10(11): 1709, doi: [10.3390/antiox10111709](https://doi.org/10.3390/antiox10111709), indexed in Pubmed: 34829580.
  40. Jung S, Kim MH, Park JH, et al. Cellular antioxidant and anti-inflammatory effects of coffee extracts with different roasting levels. *J Med Food.* 2017; 20(6): 626–635, doi: [10.1089/jmf.2017.3935](https://doi.org/10.1089/jmf.2017.3935), indexed in Pubmed: 28581877.
  41. Paiva C, Beserra B, Reis C, et al. Consumption of coffee or caffeine and serum concentration of inflammatory markers: A systematic review. *Crit Rev Food Sci Nutr.* 2019; 59(4): 652–663, doi: [10.1080/10408398.2017.1386159](https://doi.org/10.1080/10408398.2017.1386159), indexed in Pubmed: 28967799.
  42. Tian L, Su CP, Wang Q, et al. Chlorogenic acid: A potent molecule that protects cardiomyocytes from TNF- $\alpha$ -induced injury via inhibiting NF- $\kappa$ B and JNK signals. *J Cell Mol Med.* 2019; 23(7): 4666–4678, doi: [10.1111/jcmm.14351](https://doi.org/10.1111/jcmm.14351), indexed in Pubmed: 31033175.
  43. Qin L, Zang M, Xu Y, et al. Chlorogenic acid alleviates hyperglycemia-induced cardiac fibrosis through activation of the NO/cGMP/PKG pathway in cardiac fibroblasts. *Mol Nutr Food Res.* 2021; 65(2): e2000810, doi: [10.1002/mnfr.202000810](https://doi.org/10.1002/mnfr.202000810), indexed in Pubmed: 33200558.
  44. Liu JC, Chen PY, Hao WR, et al. Cafestol inhibits high-glucose-induced cardiac fibrosis in cardiac fibroblasts and type 1-like diabetic rats. *Evid Based Complement Alternat Med.* 2020; 2020: 4503747, doi: [10.1155/2020/4503747](https://doi.org/10.1155/2020/4503747), indexed in Pubmed: 33488743.
  45. Uto-Kondo H, Ayaori M, Ogura M, et al. Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages. *Circ Res.* 2010; 106(4): 779–787, doi: [10.1161/CIRCRESAHA.109.206615](https://doi.org/10.1161/CIRCRESAHA.109.206615), indexed in Pubmed: 20075335.
  46. Gebeyehu GM, Feleke DG, Molla MD, et al. Effect of habitual consumption of Ethiopian Arabica coffee on the risk of cardiovascular diseases among non-diabetic healthy adults. *Heliyon.* 2020; 6(9): e04886, doi: [10.1016/j.heliyon.2020.e04886](https://doi.org/10.1016/j.heliyon.2020.e04886), indexed in Pubmed: 32995603.
  47. Hsu TW, Tantoh DM, Lee KJ, et al. Genetic and non-genetic factor-adjusted association between coffee drinking and high-density lipoprotein cholesterol in Taiwanese adults: stratification by sex. *Nutrients.* 2019; 11(5), doi: [10.3390/nu11051102](https://doi.org/10.3390/nu11051102), indexed in Pubmed: 31108953.
  48. Beller E, Lorbeer R, Keeser D, et al. Significant impact of coffee consumption on mr-based measures of cardiac function in a population-based cohort study without manifest cardiovascular disease. *Nutrients.* 2021; 13(4), doi: [10.3390/nu13041275](https://doi.org/10.3390/nu13041275), indexed in Pubmed: 33924572.
  49. Stevens LM, Linstead E, Hall JL, et al. Association between coffee intake and incident heart failure risk: a machine learning analysis of the FHS, the ARIC study, and the CHS. *Circ Heart Fail.* 2021; 14(2): e006799, doi: [10.1161/CIRCHEARTFAILURE.119.006799](https://doi.org/10.1161/CIRCHEARTFAILURE.119.006799), indexed in Pubmed: 33557575.
  50. Svingen GFT, Zuo H, Ueland PM, et al. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation. *Int J Cardiol.* 2018; 267: 100–106, doi: [10.1016/j.ijcard.2018.04.128](https://doi.org/10.1016/j.ijcard.2018.04.128), indexed in Pubmed: 29957250.
  51. Gawałko M, Agbaedeng TA, Saljic A, et al. Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. *Cardiovasc Res.* 2021 [Epub ahead of print], doi: [10.1093/cvr/cvab292](https://doi.org/10.1093/cvr/cvab292), indexed in Pubmed: 34550344.

52. Zhou W, Cheng Y, Zhu P, et al. Implication of gut microbiota in cardiovascular diseases. *Oxid Med Cell Longev*. 2020; 2020: 5394096, doi: [10.1155/2020/5394096](https://doi.org/10.1155/2020/5394096), indexed in Pubmed: 33062141.
53. Iglesias-Carres L, Essenmacher LA, Racine KC, et al. Development of a high-throughput method to study the inhibitory effect of phytochemicals on trimethylamine formation. *Nutrients*. 2021; 13(5), doi: [10.3390/nu13051466](https://doi.org/10.3390/nu13051466), indexed in Pubmed: 33925806.
54. González S, Salazar N, Ruiz-Saavedra S, et al. Long-Term coffee consumption is associated with fecal microbial composition in humans. *Nutrients*. 2020; 12(5), doi: [10.3390/nu12051287](https://doi.org/10.3390/nu12051287), indexed in Pubmed: 32369976.
55. Mills CE, Tzounis X, Oruna-Concha MJ, et al. In vitro colonic metabolism of coffee and chlorogenic acid results in selective changes in human faecal microbiota growth. *Br J Nutr*. 2015; 113(8): 1220–1227, doi: [10.1017/S0007114514003948](https://doi.org/10.1017/S0007114514003948), indexed in Pubmed: 25809126.
56. Bartolomaeus H, Balogh A, Yakoub M, et al. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. *Circulation*. 2019; 139(11): 1407–1421, doi: [10.1161/CIRCULATIONAHA.118.036652](https://doi.org/10.1161/CIRCULATIONAHA.118.036652), indexed in Pubmed: 30586752.
57. Park KY, Kim HJ, Ahn HS, et al. Effects of coffee consumption on serum uric acid: systematic review and meta-analysis. *Semin Arthritis Rheum*. 2016; 45(5): 580–586, doi: [10.1016/j.semarthrit.2016.01.003](https://doi.org/10.1016/j.semarthrit.2016.01.003), indexed in Pubmed: 26905267.
58. Deng Y, Liu F, Yang X, et al. The key role of uric acid in oxidative stress, inflammation, fibrosis, apoptosis, and immunity in the pathogenesis of atrial fibrillation. *Front Cardiovasc Med*. 2021; 8: 641136, doi: [10.3389/fcvm.2021.641136](https://doi.org/10.3389/fcvm.2021.641136), indexed in Pubmed: 33718459.
59. Penso P, Serban MC, Ursioniu S, et al. Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review. *Crit Rev Food Sci Nutr*. 2018; 58(10): 1706–1714, doi: [10.1080/10408398.2016.1272045](https://doi.org/10.1080/10408398.2016.1272045), indexed in Pubmed: 28084806.
60. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. *Arch Med Sci*. 2021; 17(6): 1447–1547, doi: [10.5114/aoms/141941](https://doi.org/10.5114/aoms/141941), indexed in Pubmed: 34900032.
61. Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated lipoprotein(a) and risk of atrial fibrillation: an observational and mendelian randomization study. *J Am Coll Cardiol*. 2022; 79(16): 1579–1590, doi: [10.1016/j.jacc.2022.02.018](https://doi.org/10.1016/j.jacc.2022.02.018), indexed in Pubmed: 35450575.
62. Sivalokanathan S, Malek EA, Malhotra A. The cardiac effects of performance-enhancing medications: caffeine vs. anabolic androgenic steroids. *Diagnostics (Basel)*. 2021; 11(2), doi: [10.3390/diagnostics11020324](https://doi.org/10.3390/diagnostics11020324), indexed in Pubmed: 33671206.
63. Torquati L, Peeters G, Brown WJ, et al. A daily cup of tea or coffee may keep you moving: association between tea and coffee consumption and physical activity. *Int J Environ Res Public Health*. 2018; 15(9), doi: [10.3390/ijerph15091812](https://doi.org/10.3390/ijerph15091812), indexed in Pubmed: 30135386.
64. Elliott AD, Linz D, Mishima R, et al. Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. *Eur Heart J*. 2020; 41(15): 1479–1486, doi: [10.1093/eurheartj/ehz897](https://doi.org/10.1093/eurheartj/ehz897), indexed in Pubmed: 31951255.
65. Kistler P, Chieng D, Canovas R, et al. Regular coffee intake is associated with improved mortality in prevalent cardiovascular disease. *J Am Coll Cardiol*. 2022; 79(9): 1490, doi: [10.1016/s0735-1097\(22\)02481-0](https://doi.org/10.1016/s0735-1097(22)02481-0).
66. Marcus GM, Modrow MF, Schmid CH, et al. Individualized studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial. *JAMA Cardiol*. 2022; 7(2): 167–174, doi: [10.1001/jamacardio.2021.5010](https://doi.org/10.1001/jamacardio.2021.5010), indexed in Pubmed: 34775507.
67. Marcus GM, Rosenthal DG, Nah G, et al. The coffee and real-time atrial and ventricular ectopy (CRAVE) trial. *AHA Congress 2021 – oral presentation*.
68. Krittanawong C, Tunhasirivet A, Wang Z, et al. Is caffeine or coffee consumption a risk for new-onset atrial fibrillation? A systematic review and meta-analysis. *Eur J Prev Cardiol*. 2021; 28(12): e13–e15, doi: [10.1177/2047487320908385](https://doi.org/10.1177/2047487320908385), indexed in Pubmed: 34647581.
69. Bazal P, Gea A, Navarro AM, et al. Caffeinated coffee consumption and risk of atrial fibrillation in two Spanish cohorts. *Eur J Prev Cardiol*. 2021; 28(6): 648–657, doi: [10.1177/2047487320909065](https://doi.org/10.1177/2047487320909065), indexed in Pubmed: 34021573.
70. Kim EJ, Hoffmann TJ, Nah G, et al. Coffee consumption and incident tachyarrhythmias: reported behavior, Mendelian randomization, and their interactions. *JAMA Intern Med*. 2021; 181(9): 1185–1193, doi: [10.1001/jamainternmed.2021.3616](https://doi.org/10.1001/jamainternmed.2021.3616), indexed in Pubmed: 34279564.
71. Signori C, Meessen JM, Laaksonen R, et al. Coffee, atrial fibrillation, and circulating ceramides in patients with chronic heart failure. *J Agric Food Chem*. 2021; 69(38): 11236–11245, doi: [10.1021/acs.jafc.1c03741](https://doi.org/10.1021/acs.jafc.1c03741), indexed in Pubmed: 34533314.
72. Yuan S, Carter P, Mason AM, et al. Coffee consumption and cardiovascular diseases: a Mendelian randomization study. *Nutrients*. 2021; 13(7), doi: [10.3390/nu13072218](https://doi.org/10.3390/nu13072218), indexed in Pubmed: 34203356.
73. Yuan S, Larsson SC. No association between coffee consumption and risk of atrial fibrillation: A Mendelian randomization study. *Nutr Metab Cardiovasc Dis*. 2019; 29(11): 1185–1188, doi: [10.1016/j.numecd.2019.07.015](https://doi.org/10.1016/j.numecd.2019.07.015), indexed in Pubmed: 31558414.
74. Bodar V, Chen J, Gaziano JM, et al. Coffee consumption and risk of atrial fibrillation in the Physicians' Health Study. *J Am Heart Assoc*. 2019; 8(15): e011346, doi: [10.1161/JAHA.118.011346](https://doi.org/10.1161/JAHA.118.011346), indexed in Pubmed: 31378120.
75. Xu J, Fan W, Budoff MJ, et al. Intermittent nonhabitual coffee consumption and risk of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. *J Atr Fibrillation*. 2019; 12(1): 2205, doi: [10.4022/jafib.2205](https://doi.org/10.4022/jafib.2205), indexed in Pubmed: 31687073.
76. Abdelfattah R, Kamran H, Lazar J, et al. Does caffeine consumption increase the risk of new-onset atrial fibrillation? *Cardiology*. 2018; 140(2): 106–114, doi: [10.1159/000489843](https://doi.org/10.1159/000489843), indexed in Pubmed: 29966128.
77. Casiglia E, Tikhonoff V, Albertini F, et al. Caffeine intake reduces incident atrial fibrillation at a population level. *Eur J Prev Cardiol*. 2018; 25(10): 1055–1062, doi: [10.1177/2047487318772945](https://doi.org/10.1177/2047487318772945), indexed in Pubmed: 29692210.
78. Mostofsky E, Johansen MB, Lundbye-Christensen S, et al. Risk of atrial fibrillation associated with coffee intake: Findings from the Danish Diet, Cancer, and Health study. *Eur J Prev Cardiol*. 2016; 23(9): 922–930, doi: [10.1177/2047487315624524](https://doi.org/10.1177/2047487315624524), indexed in Pubmed: 26701875.
79. Dixit S, Stein PK, Dewland TA, et al. Consumption of caffeinated products and cardiac ectopy. *J Am Heart Assoc*. 2016; 5(1): e002503, doi: [10.1161/JAHA.115.002503](https://doi.org/10.1161/JAHA.115.002503), indexed in Pubmed: 26813889.
80. Larsson SC, Drca N, Jensen-Urstad M, et al. Coffee consumption is not associated with increased risk of atrial fibrillation: results from two prospective cohorts and a meta-analysis. *BMC Med*. 2015; 13: 207, doi: [10.1186/s12916-015-0447-8](https://doi.org/10.1186/s12916-015-0447-8), indexed in Pubmed: 26394673.
81. Cheng M, Hu Z, Lu X, et al. Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies. *Can J Cardiol*. 2014; 30(4): 448–454, doi: [10.1016/j.cjca.2013.12.026](https://doi.org/10.1016/j.cjca.2013.12.026), indexed in Pubmed: 24680173.
82. Caldeira D, Martins C, Alves LB, et al. Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis.

- sis of observational studies. *Heart*. 2013; 99(19): 1383–1389, doi: [10.1136/heartjnl-2013-303950](https://doi.org/10.1136/heartjnl-2013-303950), indexed in Pubmed: [24009307](https://pubmed.ncbi.nlm.nih.gov/24009307/).
83. Klatsky AL, Hasan AS, Armstrong MA, et al. Coffee, caffeine, and risk of hospitalization for arrhythmias. *Perm J*. 2011; 15(3): 19–25, doi: [10.7812/TPP/11-020](https://doi.org/10.7812/TPP/11-020), indexed in Pubmed: [22058665](https://pubmed.ncbi.nlm.nih.gov/22058665/).
  84. Mattioli AV, Farinetti A, Miloro C, et al. Influence of coffee and caffeine consumption on atrial fibrillation in hypertensive patients. *Nutr Metab Cardiovasc Dis*. 2011; 21(6): 412–417, doi: [10.1016/j.numecd.2009.11.003](https://doi.org/10.1016/j.numecd.2009.11.003), indexed in Pubmed: [20167459](https://pubmed.ncbi.nlm.nih.gov/20167459/).
  85. Shen J, Johnson VM, Sullivan LM, et al. Dietary factors and incident atrial fibrillation: the Framingham Heart Study. *Am J Clin Nutr*. 2011; 93(2): 261–266, doi: [10.3945/ajcn.110.001305](https://doi.org/10.3945/ajcn.110.001305), indexed in Pubmed: [21106919](https://pubmed.ncbi.nlm.nih.gov/21106919/).
  86. Conen D, Chiuve SE, Everett BM, et al. Caffeine consumption and incident atrial fibrillation in women. *Am J Clin Nutr*. 2010; 92(3): 509–514, doi: [10.3945/ajcn.2010.29627](https://doi.org/10.3945/ajcn.2010.29627), indexed in Pubmed: [20573799](https://pubmed.ncbi.nlm.nih.gov/20573799/).
  87. Mukamal KJ, Hallqvist J, Hammar N, et al. Coffee consumption and mortality after acute myocardial infarction: the Stockholm Heart Epidemiology Program. *Am Heart J*. 2009; 157(3): 495–501, doi: [10.1016/j.ahj.2008.11.009](https://doi.org/10.1016/j.ahj.2008.11.009), indexed in Pubmed: [19249420](https://pubmed.ncbi.nlm.nih.gov/19249420/).
  88. Mattioli AV, Bonatti S, Zennaro M, et al. Effect of coffee consumption, lifestyle and acute life stress in the development of acute lone atrial fibrillation. *J Cardiovasc Med (Hagerstown)*. 2008; 9(8): 794–798, doi: [10.2459/JCM.0b013e3282f64554](https://doi.org/10.2459/JCM.0b013e3282f64554), indexed in Pubmed: [18607243](https://pubmed.ncbi.nlm.nih.gov/18607243/).
  89. Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. *Am J Clin Nutr*. 2005; 81(3): 578–582, doi: [10.1093/ajcn/81.3.578](https://doi.org/10.1093/ajcn/81.3.578), indexed in Pubmed: [15755825](https://pubmed.ncbi.nlm.nih.gov/15755825/).
  90. Mattioli AV, Bonatti S, Zennaro M, et al. The relationship between personality, socio-economic factors, acute life stress and the development, spontaneous conversion and recurrences of acute lone atrial fibrillation. *Europace*. 2005; 7(3): 211–220, doi: [10.1016/j.eupc.2004.02.006](https://doi.org/10.1016/j.eupc.2004.02.006), indexed in Pubmed: [15878557](https://pubmed.ncbi.nlm.nih.gov/15878557/).
  91. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. *J Intern Med*. 2001; 250(5): 382–389, doi: [10.1046/j.1365-2796.2001.00902.x](https://doi.org/10.1046/j.1365-2796.2001.00902.x), indexed in Pubmed: [11887972](https://pubmed.ncbi.nlm.nih.gov/11887972/).
  92. Zuchinali P, Souza GC, Pimentel M, et al. Short-term effects of high-dose caffeine on cardiac arrhythmias in patients with heart failure: a randomized clinical trial. *JAMA Intern Med*. 2016; 176(12): 1752–1759, doi: [10.1001/jamainternmed.2016.6374](https://doi.org/10.1001/jamainternmed.2016.6374), indexed in Pubmed: [27749954](https://pubmed.ncbi.nlm.nih.gov/27749954/).
  93. Zuchinali P, Ribeiro PAB, Pimentel M, et al. Effect of caffeine on ventricular arrhythmia: a systematic review and meta-analysis of experimental and clinical studies. *Europace*. 2016; 18(2): 257–266, doi: [10.1093/europace/euv261](https://doi.org/10.1093/europace/euv261), indexed in Pubmed: [26443445](https://pubmed.ncbi.nlm.nih.gov/26443445/).
  94. Bertoia ML, Triche EW, Michaud DS, et al. Long-term alcohol and caffeine intake and risk of sudden cardiac death in women. *Am J Clin Nutr*. 2013; 97(6): 1356–1363, doi: [10.3945/ajcn.112.044248](https://doi.org/10.3945/ajcn.112.044248), indexed in Pubmed: [23615825](https://pubmed.ncbi.nlm.nih.gov/23615825/).
  95. de Vreede-Swagemakers JJ, Gorgels A, Weijenberg M, et al. Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease. *J Clin Epidemiol*. 1999; 52(7): 601–607, doi: [10.1016/s0895-4356\(99\)00044-x](https://doi.org/10.1016/s0895-4356(99)00044-x).
  96. Newby DE, Neilson JM, Jarvie DR, et al. Caffeine restriction has no role in the management of patients with symptomatic idiopathic ventricular premature beats. *Heart*. 1996; 76(4): 355–357, doi: [10.1136/hrt.76.4.355](https://doi.org/10.1136/hrt.76.4.355), indexed in Pubmed: [8983684](https://pubmed.ncbi.nlm.nih.gov/8983684/).
  97. Myers MG, Harris L. High dose caffeine and ventricular arrhythmias. *Can J Cardiol*. 1990; 6(3): 95–98, indexed in Pubmed: [1692755](https://pubmed.ncbi.nlm.nih.gov/1692755/).
  98. Graboys TB, Blatt CM, Lown B. The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia. *Arch Intern Med*. 1989; 149(3): 637–639, indexed in Pubmed: [2465748](https://pubmed.ncbi.nlm.nih.gov/2465748/).
  99. Myers M, Harris L, Leenen F, et al. Caffeine as a possible cause of ventricular arrhythmias during the healing phase of acute myocardial infarction. *Am J Cardiol*. 1987; 59(12): 1024–1028, doi: [10.1016/0002-9149\(87\)90842-3](https://doi.org/10.1016/0002-9149(87)90842-3).
  100. Prineas R, Jacobs D, Crow R, et al. Coffee, tea and VPB. *J Chronic Dis*. 1980; 33(2): 67–72, doi: [10.1016/0021-9681\(80\)90029-6](https://doi.org/10.1016/0021-9681(80)90029-6).
  101. de Oliveira RA, Araújo LF, de Figueiredo RC, et al. Coffee consumption and heart rate variability: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) Cohort Study. *Nutrients*. 2017; 9(7), doi: [10.3390/nu9070741](https://doi.org/10.3390/nu9070741), indexed in Pubmed: [28703735](https://pubmed.ncbi.nlm.nih.gov/28703735/).
  102. Lemery R, Pecarskie A, Bernick J, et al. A prospective placebo controlled randomized study of caffeine in patients with supraventricular tachycardia undergoing electrophysiologic testing. *J Cardiovasc Electrophysiol*. 2015; 26(1): 1–6, doi: [10.1111/jce.12504](https://doi.org/10.1111/jce.12504), indexed in Pubmed: [25081280](https://pubmed.ncbi.nlm.nih.gov/25081280/).
  103. Notarius CF, Floras JS. Caffeine enhances heart rate variability in middle-aged healthy, but not heart failure subjects. *J Caffeine Res*. 2012; 2(2): 77–82, doi: [10.1089/jcr.2012.0010](https://doi.org/10.1089/jcr.2012.0010), indexed in Pubmed: [24761268](https://pubmed.ncbi.nlm.nih.gov/24761268/).
  104. Richardson T, Baker J, Thomas PW, et al. Randomized control trial investigating the influence of coffee on heart rate variability in patients with ST-segment elevation myocardial infarction. *QJM*. 2009; 102(8): 555–561, doi: [10.1093/qjmed/hcp072](https://doi.org/10.1093/qjmed/hcp072), indexed in Pubmed: [19531728](https://pubmed.ncbi.nlm.nih.gov/19531728/).
  105. Strubelt O, Diederich KW. Experimental treatment of the acute cardiovascular toxicity of caffeine. *J Toxicol Clin Toxicol*. 1999; 37(1): 29–33, doi: [10.1081/ct-100102405](https://doi.org/10.1081/ct-100102405), indexed in Pubmed: [10078157](https://pubmed.ncbi.nlm.nih.gov/10078157/).
  106. Robertson D, Frölich JC, Carr RK, et al. Effects of caffeine on plasma renin activity, catecholamines and blood pressure. *N Engl J Med*. 1978; 298(4): 181–186, doi: [10.1056/NEJM197801262980403](https://doi.org/10.1056/NEJM197801262980403), indexed in Pubmed: [339084](https://pubmed.ncbi.nlm.nih.gov/339084/).
  107. Fabrizio C, Desiderio M, Coyne RF. Electrocardiogram abnormalities of caffeine overdose. *Circ Arrhythm Electrophysiol*. 2016; 9(7): e003088, doi: [10.1161/CIRCEP.115.003088](https://doi.org/10.1161/CIRCEP.115.003088), indexed in Pubmed: [27406599](https://pubmed.ncbi.nlm.nih.gov/27406599/).
  108. Nwabuo CC, Betoko AS, Reis JP, et al. Coffee and tea consumption in the early adult lifespan and left ventricular function in middle age: the CARDIA study. *ESC Heart Fail*. 2020; 7(4): 1510–1519, doi: [10.1002/ehf2.12684](https://doi.org/10.1002/ehf2.12684), indexed in Pubmed: [32449612](https://pubmed.ncbi.nlm.nih.gov/32449612/).
  109. Karabegović I, Portilla-Fernandez E, Li Y, et al. Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption. *Nat Commun*. 2021; 12(1): 2830, doi: [10.1038/s41467-021-22752-6](https://doi.org/10.1038/s41467-021-22752-6), indexed in Pubmed: [33990564](https://pubmed.ncbi.nlm.nih.gov/33990564/).
  110. Hyppönen E, Zhou A. Cardiovascular symptoms affect the patterns of habitual coffee consumption. *Am J Clin Nutr*. 2021; 114(1): 214–219, doi: [10.1093/ajcn/nqab014](https://doi.org/10.1093/ajcn/nqab014), indexed in Pubmed: [33711095](https://pubmed.ncbi.nlm.nih.gov/33711095/).
  111. Surma S, Witek A. Coffee consumption during pregnancy - what the gynecologist should know? Review of the literature and clinical studies. *Ginekol Pol*. 2022; 93(7): 591–600, doi: [10.5603/GPa2022.0061](https://doi.org/10.5603/GPa2022.0061), indexed in Pubmed: [35894479](https://pubmed.ncbi.nlm.nih.gov/35894479/).